维普期刊资源整合服务平台（V6.5）

160篇 您的检索式：作者名="MCDERMOTT DF"

选中清除导出查看参考文献查看引证文献引用追踪共8页首页上一页第1页下一页末页 /8 跳转

	题名	作者	年代	出处	被引量
1	Random- ized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma 显示文摘	McDermott DF Regan MM Clark JI	2005	J Clin Oncol2005，23，1：	1
2	Improved survival with ipilimumab in patients with metastatic melanoma 显示文摘	Hodi FS O'Day SJ McDermott DF	2010	N Engl J Med2010，363，8：	1
3	Improved survival with ipilimumab in patients with metastatic melanoma 显示文摘	Hedi FS O'Day SI McDermott DF	2010	New Engl J Med2010，363，8：	1
4	Improved survival with ipilimumab in patients with metastatic melanoma显示文摘	Hodi FS O'day SJ Mcdermott DF	2010	N Engl J Med2010，363，8：	1
5	Randomized phase 11I trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma显示文摘	McDermott DF Regan MM Clark JI	2005	J Clin Oncol2005，23，1：	1
6	Phase Ⅱ trial of ipilimumab monotherapy in melanoma patients with brain metastases显示文摘	Lawrence DP Hamid O McDermott DF		0，，15：	1
7	Improved survival with ipilimumab in patients with metastatic mel-anoma显示文摘	Hodi FS O' Day S J McDermott DF	2010	N Engl J Med2010，363，8：	1
8	A randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinomar 显示文摘	McDermott DF Regan MM Clark JI	2005	J Clin Oncol2005，23，1：	1
9	Applicayion of IL - 2 and other cyto-kines in renal cancer显示文摘	McDermott DF Atkins MB	2004	Expret Opin Biol Ther2004，4940，：	1
10	Improved survival with ipilimumab in pa- tients with metastatic melanoma 显示文摘	Hodi FS O'Day SJ McDermott DF	2010	N Engl J Med2010，363，8：	1
11	Improved survival with ipilimumab in patients with metastatic melanoma显示文摘	Hodi FS O'Day SJ McDermott DF		0，，8：	1
12	Immunotherapy for renal cell carcinoma显示文摘	Rosenblatt J McDermott DF	2011	Hematol Oncol Clin North Am2011，25，4：	1
13	The high-dose aldesleukin ( IL-2 ) 'select' trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma 显示文摘	Clement JM McDermott DF	2009	Clin Genitourin Cancer2009，7，2：	1
14	Double- study of the combination of in patients with advanced melanoma: a report from the 11715 Study Group显示文摘	McDermott DF Sosman JA blind randomized phase Ⅱ sorafenib and dacarbazine Gonzalez R	2008	J Clin Oncol2008，26，13：	1
15	Phase Ⅱ trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases 显示文摘	Amaravadi RK Schuchter LM McDermott DF	2009	Clin Cancer Res2009，15，24：	1
16	Safety and efficacy results of the advanced renal cell carcinoma sorafenih expanded access program in North America 显示文摘	Stadler WM Figlin RA McDermott DF	2010	Cancer2010，116，5：	1
17	Improved survival with ipilimumab in patients with metastatic melanoma 显示文摘	Hodi FS O'Day SJ McDermott DF	2010	N Engl J Med2010，363，8：	1
18	Immunotherapy of metastatic renal cell carcinoma显示文摘	McDermott DF	2009	Cancer2009，115，10：	1
19	PD-1 as a potential target in cancer therapy显示文摘	McDermott DF Atkins MB	2013	Cancer Meal2013，2，5：	1
20	Improved survivalwith ipilimumab in patients with metastatic melanoma 显示文摘	Hodi FS O^Day SJ McDermott DF	2010	N Engl J Med2010，363，8：	1

返回顶部每页显示：

共8页首页上一页第1页下一页末页 /8 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示